Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Inman

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|February 27, 2026
Integrated Multi-Omics Enabled by Sequential Extraction for Comprehensive Molecular Profiling of Small Extracellular VesiclesAndrew J Perciaccante, Holden T Rogers, Yanlong Zhu, et al.
Analytical Chemistry|June 22, 2026
Integrated Multiomics Enabled by Sequential Extraction for Comprehensive Molecular Profiling of Small Extracellular VesiclesAndrew J Perciaccante, Holden T Rogers, Yanlong Zhu, et al.
Nature Communications|May 1, 2020
A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cellsBong Hwan Sung, Ariana von Lersner, Jorge Guerrero, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Exosomes are specialized vehicles to induce fibronectin assemblyBong Hwan Sung, Merlyn Emmanuel, Metti K Gari, et al.
British Journal of Clinical Pharmacology|December 20, 2018
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patientsGeorgios Vlasakakis, Antonella Napolitano, Ruth Barnard, et al.
The Lancet. Rheumatology|January 27, 2024
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging studyChristopher D Buckley, Jesus A Simón-Campos, Vyacheslav Zhdan, et al.
The Lancet. Rheumatology|January 27, 2024
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic studyMark C Genovese, Mario Berkowitz, Philip G Conaghan, et al.
Scientific Data|June 3, 2025
The Areal Typology of Languages of the Americas (ATLAs) databaseDavid Inman, Natalia Chousou-Polydouri, Marine Vuillermet, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept studyJagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez, et al.
Open Forum Infectious Diseases|August 14, 2023
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical TrialAdrienne E Shapiro, Elias Sarkis, Jude Acloque, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|February 27, 2026
Integrated Multi-Omics Enabled by Sequential Extraction for Comprehensive Molecular Profiling of Small Extracellular VesiclesAndrew J Perciaccante, Holden T Rogers, Yanlong Zhu, et al.
Analytical Chemistry|June 22, 2026
Integrated Multiomics Enabled by Sequential Extraction for Comprehensive Molecular Profiling of Small Extracellular VesiclesAndrew J Perciaccante, Holden T Rogers, Yanlong Zhu, et al.
Nature Communications|May 1, 2020
A live cell reporter of exosome secretion and uptake reveals pathfinding behavior of migrating cellsBong Hwan Sung, Ariana von Lersner, Jorge Guerrero, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Exosomes are specialized vehicles to induce fibronectin assemblyBong Hwan Sung, Merlyn Emmanuel, Metti K Gari, et al.
British Journal of Clinical Pharmacology|December 20, 2018
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patientsGeorgios Vlasakakis, Antonella Napolitano, Ruth Barnard, et al.
The Lancet. Rheumatology|January 27, 2024
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging studyChristopher D Buckley, Jesus A Simón-Campos, Vyacheslav Zhdan, et al.
The Lancet. Rheumatology|January 27, 2024
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic studyMark C Genovese, Mario Berkowitz, Philip G Conaghan, et al.
Scientific Data|June 3, 2025
The Areal Typology of Languages of the Americas (ATLAs) databaseDavid Inman, Natalia Chousou-Polydouri, Marine Vuillermet, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept studyJagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez, et al.
Open Forum Infectious Diseases|August 14, 2023
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical TrialAdrienne E Shapiro, Elias Sarkis, Jude Acloque, et al.
Pageof 3